Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Other Non-Current Assets (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Other Non-Current Assets for 4 consecutive years, with $2.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Other Non-Current Assets rose 43.18% to $2.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was $2.0 million, a 43.18% increase, with the full-year FY2024 number at $2.0 million, up 43.18% from a year prior.
  • Other Non-Current Assets was $2.0 million for Q4 2024 at Lyra Therapeutics, up from $1.4 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $7.5 million in Q3 2023 to a low of $243000.0 in Q2 2021.
  • A 4-year average of $1.6 million and a median of $1.1 million in 2022 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: soared 471.43% in 2022, then crashed 57.57% in 2023.
  • Lyra Therapeutics' Other Non-Current Assets stood at $762000.0 in 2021, then skyrocketed by 330.58% to $3.3 million in 2022, then plummeted by 57.57% to $1.4 million in 2023, then soared by 43.18% to $2.0 million in 2024.
  • Per Business Quant, the three most recent readings for LYRA's Other Non-Current Assets are $2.0 million (Q4 2024), $1.4 million (Q4 2023), and $7.5 million (Q3 2023).